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Abstract 
Glioblastoma multiforme (GBM) is the most aggressive malignant primary brain tumor in adults. 
Several studies have shown that glioma cells up-regulate the expression of xCT (SLC7A11), the 
catalytic subunit of system xc–, a transporter involved in cystine import, that modulates 
glutathione production and glioma growth. However, the role of system xc– in regulating the 
sensitivity of glioma cells to chemotherapy is currently debated. Inhibiting system xc– with 
sulfasalazine decreased glioma growth and survival via redox modulation, and use of the 
chemotherapeutic agent temozolomide together with sulfasalazine had a synergistic effect on cell 
killing. To better understand the functional consequences of system xc– in glioma, stable 
SLC7A11 knock-down and over-expressing U251 glioma cells were generated. Modulation of 
SLC7A11 did not alter cellar proliferation but over-expression did increase anchorage-
independent cell growth. Knock-down of SLC7A11 increased basal ROS and decreased 
glutathione generation resulting in increased cell death under oxidative and genotoxic stress. 
Over-expression of SLC7A11 resulted in increased resistance to oxidative stress and decreased 
chemosensitivity to temozolomide. In addition, SLC7A11 over-expression was associated with 
altered cellular metabolism including increased mitochondrial biogenesis, oxidative 
phosphorylation and ATP generation. These results suggest that expression of SLC7A11 in the 
context of glioma contributes to tumorigenesis, tumor progression, and resistance to standard 
chemotherapy.  
Implications: SLC7A11, in addition to redox modulation, appears to be associated with 
increased cellular metabolism and is a mediator of temozolomide resistance in human glioma, 
thus making system xC– a potential therapeutic target in GBM. 
Key words: SLC7A11; glioma; oxidative stress; glutathione; chemoresistance, metabolism 
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Introduction 
Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and 
aggressive primary brain tumor in adults; patient survival averages only 14 months after 
diagnosis (1). The standard-of-care for patients with newly diagnosed GBM includes aggressive 
safe tumor resection followed by radiotherapy with concomitant systemic chemotherapy using 
the alkylating agent temozolomide (TMZ) (2). Unfortunately, patients with high grade gliomas 
inevitably progress or relapse an average of only 6.9 months after treatment (3). Therapeutic 
options for recurrent GBM are limited and generally not effective. One of the main causes of 
treatment failure in GBM patients is resistance to post-operative radiation and chemotherapy. 
Many mechanisms contribute to the development of drug resistance, including DNA repair, drug 
uptake and efflux, apoptosis and glutathione-mediated cellular detoxification pathways (4). Thus, 
an improved understanding of the molecular mechanisms involved in glioma progression and 
survival, as well as mediators of TMZ resistance, could lead to development of more effective 
therapeutic strategies.     
One of the mechanisms for chemo- and radiotherapy is to disproportionately increase 
intracellular reactive oxygen species (ROS) to induce cell cycle arrest, senescence and apoptosis 
(5). Accumulation of ROS can trigger apoptosis due to oxidative damage to DNA, 
macromolecules, lipids and mitochondria. However, up-regulation of antioxidant systems is 
observed in various tumors making them more resistant to chemotherapy (6). Approaches to 
maximally exploit ROS-mediated cell death by combining drugs that induce ROS generation 
with compounds that suppress cellular antioxidant capacity have been proposed years ago (7). 
System xc–, a sodium-independent membrane transporter, couples the influx of 
extracellular cystine to the efflux of glutamate (8). Expression of system xc–, specifically the 
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catalytic domain xCT, is up-regulated in gliomas, and several studies have shown over-
expression confers a growth advantage, either through increased extracellular glutamate levels 
that promote neuronal cell death or through increased import of cystine that is converted to 
cysteine (8-11). Cysteine is the rate-limiting precursor for generating the major antioxidant 
glutathione (GSH). GSH can neutralize intracellular ROS or be conjugated by glutathione S-
transferases to xenobiotic agents, which are then exported out of the cell (12, 13).  
There is accumulating evidence that GSH and system xc– may mediate resistance of 
cancer to cytotoxin-based therapies (5). Radiation therapy-resistant glioma cells exhibited a 5-
fold increase in the expression of antioxidant enzymes such as superoxide dismutase, glutathione 
peroxidase, and glutathione reductase that maintain redox balance (14). High intracellular GSH 
levels in cancer cells have also been associated with drug resistance and detoxification of 
alkylating agents. System xc– has been shown to maintain intracellular GSH levels in ovarian 
cancer cells, resulting in cisplatin resistance (15). Inhibition of system xc– in pancreatic cancer 
cells led to growth arrest and over-expression led to gemcitabine resistance (16). Recent findings 
also support the hypothesis of a correlation between adaption to oxidative stress, low 
mitochondrial ROS, enhanced mitochondrial respiration and resistance to chemotherapy drugs 
(17).  
In this study, we show that xCT (SLC7A11) was highly expressed in established glioma 
cell lines and that treating cells with sulfasalazine (SSZ), an inhibitor of system xc–, decreased 
glioma growth and increased ROS-mediated cell death. Inhibiting system xc– in U251 glioma 
cells with SSZ concomitant with TMZ treatment had a synergistic killing effect. However, stable 
knock-down of SLC7A11 in U251 glioma cells did not alter cell growth or viability under basal 
conditions, despite changes in redox balance. Over-expression of SLC7A11 resulted in 
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anchorage-independence and resistance to oxidative stress, while SLC7A11 knock-down 
decreased anchorage-dependent cell growth and resistance to oxidative stress. Knocking-down 
expression of SLC7A11 in U251 glioma cells also increased their sensitivity to TMZ. In contrast, 
U251 cells in which SLC7A11 was over-expressed had decreased sensitivity to TMZ and reduced 
apoptosis. Over-expression of SLC7A11 in U251 glioma cells also resulted in an up-regulation of 
genes involved in cellular metabolism, increased mitochondrial biogenesis, oxidative 
phosphorylation, and ATP production while maintaining low cytoplasmic and mitochondrial 
ROS levels. These results suggest that high expression of SLC7A11/system xc– activity may 
confer resistance of glioma to TMZ treatment by increasing GSH production for redox balance 
and promoting cellular metabolism. 
 
Materials and Methods 
Cell Culture 
Human glioma cell lines (U251 and U87) and normal primary human astrocytes (pNHA) were 
purchased from American Type Culture Collection (ATCC) and cultured as previously described 
(18). The primary high grade glioma line PBT017 was obtained and cultured as previously 
described (18). For genotoxic  or oxidative stress studies, cells were treated 24 h after plating 
with either 300 μM TMZ for 72 h or 100 μM H2O2 for 6 h.  
 
Orthotopic Transplantation and Histopathological Analysis 
 In vivo studies were carried out in an orthotopic U251, U87, and PBT017 human glioma mouse 
model. Tumors were established by stereotactic, intracranial injection of 2 × 105 cells into the 
frontal lobe of NOD-scid mice. At 4 weeks, mice were perfused transcardially with 4% 
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paraformaldehyde in PBS. Brains were harvested and formalin-fixed paraffin-embedded sections 
were stained with hematoxylin-eosin to confirm the presence of tumors.  To assess xCT protein 
expression in vivo, sections were incubated overnight with a goat anti-human polyclonal xCT 
antibody (LS-B4345, LifeSpan Biosciences, Inc.) followed by incubation with secondary 
antibodies conjugated to horseradish peroxidase and detected using a DAB Peroxidase Substrate 
Kit (Vector Laboratories, Inc.)  
 
RNA Isolation, cDNA Synthesis, and Quantitative Real-time-PCR   
Total RNA was extracted using Trizol reagent. Synthesis of cDNA was performed using the 
BioRad cDNA synthesis kit. SYBR green PCR master mix (Life Technologies) was used for 
quantitative real-time PCR (qRT-PCR) monitored with a C1000 Thermal Cycler (BioRad) as 
previously described.(19) Reaction conditions for qRT-PCR were as follows: 1 cycle of 3 min at 
95ºC; 39 cycles of 10 s at 95ºC, 10 s at 55ºC,  30 s at 72 ºC; 1 cycle of 10 s at  95°C; and a 
melting curve of  5 s at 65°C - 95°C. A standard linear curve was generated using pooled sample 
DNA and the threshold exponential amplification cycle (CT) was calculated by system software. 
The following primer sequences were used: human SLC7A11: 5’-
CTGAGGAGCTGCTGCTTTCAAA-3’ and 5’-AGGAGAGGGCAACAAAGATCGGAA-3’; 
and human GAPDH: 5’-ACCAAATCCGTTGACTCCGACCTT-3’ and 5’-
TTCGACAGTCAGCCGCATCTTCTT-3’.  
 
Western Blot Analysis 
Total protein extraction and Western blot analysis were performed as previously described.(9) 
The following primary antibodies were used: polyclonal goat anti-xCT (GTX89082; GeneTex), 
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and rabbit monoclonal anti-active caspase-3 (ab32042; Abcam). Immunoreactivity was detected 
with a polyclonal rabbit-anti goat horseradish peroxide (HRP)-conjugated secondary antibody, 
and a polyclonal rabbit-anti goat HRP-conjugated secondary antibody, respectively. Mouse β-
actin (A1978; Sigma-Aldrich) was used as a loading control and detected with polyclonal goat- 
anti mouse HRP- conjugated secondary antibody (Cat. 1706516; BioRad).  
 
Immunofluorescence Microscopy 
Cells were fixed with 4% paraformaldehyde and stained with a rabbit polyclonal antibody to 
xCT (NB-300-318; Novus Biologics). Immune complexes were detected with an AlexaFlour-488 
conjugated secondary antibody (Molecular Probes). Nuclei were counterstained with DAPI 
(Vectastain). Images were acquired with a LSM 510 Meta Inverted 2-photon confocal 
microscope. 
 
Production of shSLC7A11 and SLC7A11 U251 Glioma Cell Lines 
Lentivirus particles were produced by transfection of HEK 293T cells with either 15 μg of 
human TRC-pLKO.1-SLC7A11 shRNA (TRCN0000043123, TRCN0000043125, 
TRCN0000043126, TRCN0000288865, or TRCN0000380471), 15 μg of pLK01-non-targeting 
shRNA (Mission shRNA, Sigma-Aldrich) or 15 μg of a human SLC7A11-pLX304 plasmid 
(DNASU Plasmid Repository) using calcium phosphate coprecipitation.  The culture medium 
was replaced with fresh 10% FBS in 1xDMEM after 8 h and supernatant was collected 48 h after 
transfection. After determination of viral titers, U251 cells were incubated with a viral vector 
containing the appropriate over-expressing RNA, shRNA, or control shRNA, using a multiplicity 
of infection of 0.5. Blasticidin (1.0 μg/mL) (Sigma-Aldrich) or puromycin (10 μg/mL) (Sigma-
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Aldrich) selection was used to obtain stable recombinant SLC7A11 over-expressing and 
shSLC7A11 knock-down U251 cells, respectively. Parental U251 cells served as controls for 
SLC7A11 over-expressing cells while cells transduced with an empty vector served as controls 
for the SLC7A11 knock-down cells. 
 
ROS Production  
Production of intracellular ROS under basal and treatment conditions was measured using the 
cell-permeant 2’,7’-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen). To evaluate 
the direct production of mitochondrial ROS in cells, MitoTracker Red CM-H2XRos, which is 
dependent on the mitochondria membrane potential (ΔΨm), was used. At the indicated time-
points, cells were incubated (6% CO2, 37ºC, 30 min) with either 5μM H2DCFDA or 500 nM 
MitoTracker Red. Media was aspirated; cells collected with Accutase and spun down at 1200 x g 
for 5 min. Cells were then resuspended in flow buffer (1% FBS in PBS) and analyzed using a 
BD Accuri C6 Flow Cytometer. 
 
Glutamate Measurement 
Glutamate was measured in media samples using the BioProfile 100 Plus (Nova Biomedical). 
SLC7A11 modified and control U251 cells were cultured in glutamate free DMEM for 24 h. 
After culture, 600 µL of media was removed from each sample dish and analyzed according to 
the manufacturer’s instructions.  
 
Assessment of Mitochondria Function 
Mitochondrial function was examined by staining with the mitochondrial membrane potential (ΔΨm)-
sensitive fluorochrome MitoTracker Red CMXRos. Cells (200,000 cells/well) were plated (12-well plate), 
 9
cultured overnight, and then incubated (60 minutes, 37ºC) with 500 nM of MitoTracker Red CMXRos. 
After two washes with PBS, cells were fixed with methanol:acetone (3:1) for 10 min. Cells were washed 
twice in PBS, mounted in Dako Fluorescent Mounting Medium and imaged on a LSM 510 Meta Inverted 
2-photon confocal microscope. 
 
Measurement of Apoptosis  
Apoptosis ratios were analyzed using the Alexa Fluor 488 AnnexinV/Dead Cell Apoptosis kit 
(Invitrogen) according to the manufacturer’s instructions. Samples were analyzed on a BD 
Accuri C6 Cytometer, and Annexin V-/ PI- cells were used as unstained controls. 
 
Quantification of Total Cellular ATP  
To measure intracellular ATP, cells were lysed in buffer (200 mM Tris, 2 mM EDTA, 150 mM 
NaCl, 0.5% Triton X-100) and CellTiter-Glo Luminescence Viability Assay (Promega) was 
performed according to the manufacturer’s protocol. An ATP standard curve was generated by 
serial dilutions of a 1 mg ATP stock (Sigma Aldrich). Luminescence measured using a 
SpectraMax M3 (Molecular Devices). 
 
Glutathione Measurement 
At the indicated time-points, cells were lysed with 200 μl of MES buffer (0.4 M 2-(N-
morpholino) ethanesulphonic acid, 0.1 M phosphate, 2 mM EDTA, pH 6.0) and sonicated. 
Protein concentrations were quantified using the BCA Protein Assay (Thermo Scientific). A 
Glutathione Assay Kit (Caymen Chemical) was used to quantify total GSH and glutathione 
disulfide (GSSG) according to manufacturer’s protocol.  Absorbance was measured at 405 nm 
using a SpectraMax M3.  
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Cell Viability and Proliferation Assays  
Cell counting kit-8 (CCK-8; Dojindo Molecular Technologies) was used to measure cell viability 
according to the manufacturer’s protocol. Absorbance was measured at 450 nm using a 
SpectraMax M3. A colorimetric immunoassay (Roche Diagnostics) was used according to the 
manufacturer’s protocol to quantify cell proliferation based on the measurement of BrdU 
incorporation during DNA synthesis. Absorbance was measured at 370 nm using a SpectraMax 
M3. Cell numbers at each time-point were determined by flow cytometry (Guava EasyCyte, 
Millipore) using Guava Viacount (Millipore). 
 
Soft Agar Assay for Anchorage-Independent Cell Growth 
Anchorage-independent growth was determined by seeding 2.5 × 104 cells per 12 well in 0.35% 
agar on top of a base layer containing 0.4% agar. Plates were incubated at 37 °C at 5% CO2 in a 
humidified incubator for 30 days and stained with 0.005% crystal violet for 1 h. Colonies >0.1 
mm in diameter were counted under a microscopic field at ×10 magnifications. 
 
Transmission Electron Microscopy 
Cultured cells were pelleted and cryo-fixed in a Leica EM PACT2 high pressure freezer (~2,000 
bars). In a Leica automated freeze substitution system AFS2, cryo-fixed specimens were freeze-
substituted in anhydrous acetone containing 2% osmium tetroxide. The temperature progression 
was 8 h at -90°C, -90°C to -60°C at 5°C/h, -60°C for 16 h, -60°C to 0°C at 5°C/h. Cells were 
held at 0°C until time for further processing, when they are warmed to room temperature, rinsed 
in pure acetone, infiltrated and embedded in Epon812 at 60°C for 48 hours. Ultra-thin sections 
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(~70 nm thick) were cut using a Leica Ultra cut UCT ultramicrotome with a diamond knife, 
picked up on 200 mesh nickel EM grids. For morphology, grids were stained with 2% uranyl 
acetate in 70% ethanol for 1 minute followed Reynold’s lead citrate staining for 1 minute. 
Electron microscopy was done on an FEI Tecnai 12 transmission electron microscope equipped 
with a CCD camera.  
 
Oxygen Consumption and Extracellular Acidification Rate 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) was determined 
using XF24 Extracellular Flux analyzer (Seahorse Bioscience, North Billerica, MA). Briefly, 
cells (20,000/well) were plated into XF24 polystyrene cell culture plates (Seahorse Bioscience) 
and incubated for 24  hours in a humidified 37°C incubator with 10% CO2 (DMEM medium 
with 10%FBS). The following day, cells were washed, fresh assay media (2mM L-Glutamine + 
2mM Pyruvate + 25mM Glucose in XF Base Media; pH to ~7.35) was added and cells incubated 
in a 37°C/non-CO2 incubator for 60 minutes prior to the start of an assay. Sensor cartridges were 
calibrated and loaded to dispense three metabolic inhibitors sequentially at specific timepoints: 
oligomycin (inhibitor of ATP synthase, 8uM/port), followed by FCCP (a protonophore and 
uncoupler of mitochondrial oxidative phosphorylation, 18uM/port), followed by the addition of 
rotenone (mitochondrial complex I inhibitor, 25uM/port). Basal OCR and ECAR were measured, 
as well as changes in oxygen consumption caused by the addition of the metabolic inhibitors 
described above. Cells were treated with trypsin and then counted to determine the cell number 
in each well after the assay. OCR and ECAR were reported as normalized rates (pmoles/cell for 
OCR and mpH/cell for ECAR) or expressed as a percentage of the baseline oxygen consumption. 
Each datum was determined minimally in replicates of five. Several parameters were deducted 
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from the changes in oxygen consumption including ATP turnover, proton leak, maximal 
respiratory capacity, and mitochondrial reserve capacity (= [maximum mitochondrial capacity] – 
[basal OCR]). 
 
RNA-Sequence Data Generation and Analysis 
Sequencing libraries were prepared with TruSeq RNA Sample Preparation Kit V2 (Illumina, San 
Diego) according to the manufacturer's protocol with minor modifications. Briefly, 500 ng of 
total RNA from each sample was used for polyadenylated RNA enrichment with oligo dT 
magnetic beads, and the poly(A) RNA was fragmented with divalent cations under elevated 
temperature. First-strand cDNA synthesis produced single-stranded DNA copies from the 
fragmented RNA by reverse transcription. After second-strand cDNA synthesis, the double-
stranded DNA underwent end repair, and the 3′ ends were adenylated. Finally, universal adapters 
were ligated to the cDNA fragments, and 10 cycles of PCR were performed to produce the final 
sequencing library. Library templates were prepared for sequencing using cBot cluster 
generation system (Illumina) with TruSeq SR Cluster V3 Kit. Sequencing run was performed in 
single read mode of 51 cycle of read1 and 7 cycles of index read using Illumina HiSeq 2500 
platform with TruSeq SBS V3 Kits. Real-time analysis (RTA) software was used to process the 
image analysis and base calling. Sequencing runs generated approximately 40 million single 
reads for each sample. The refSeq annotation for the hg19 version of the human genome was 
used to create a transcriptome Bowtie (20) index (version 0.12.7), to which reads were aligned 
with the following settings: “-v 3 -a”. Gene expression levels were estimated using eXpress (21) 
(version 1.4.1), and the effective count values were used as input to DESeq (22) for evaluating 
differential expression. 
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Statistical Analysis  
Experiments were performed in at least triplicate and repeated at least three independent times. 
Statistical significance was determined by difference of means between two groups and was 
calculated using Student’s t test. All reported p-values were two-sided; P<0.05 was considered 
significant. 
 
 
Results 
SLC7A11/xCT is Up-regulated in Glioma Cell Lines and Inhibition Induces ROS-Mediated Cell 
Death 
The expression of SLC7A11 and xCT in human astrocytoma cell lines was assessed by qRT-PCR 
and Western blot analysis, respectively. Both the U87 and U251 established astrocytoma cell 
lines had greater SLC7A11 gene (Fig. 1A) and xCT protein expression (Fig. 1B) as compared to 
primary normal human astrocytes (pNHAs). Protein expression was also retained when U87 and 
U251 cells or a primary high grade glioma line, PBT017, were orthotopically transplanted into 
NOD-scid mice (Fig. 1C).  
To determine if system xc– transport activity is necessary for the survival of glioma cells, 
we treated U251 glioma cells with increasing doses of the pharmacologic inhibitor SSZ. BrdU 
incorporation, which is a relative measure of cellular proliferation, showed a dose-dependent 
decrease with higher SSZ doses (1000 μM and 1500 μM) at multiple time points (Suppl. Fig 
1A). After 72 h of SSZ treatment, there was a dose-dependent decrease in U251 cell numbers 
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(Fig. 1D). A majority of the cells were lost at the higher doses for the cell count assay; therefore 
we chose to use 500 μM SSZ for subsequent assays. To determine whether the decrease in cell 
growth was due to apoptosis, Annexin V-PI staining was performed. Treatment of U251 cells 
with 500 μM SSZ resulted in a large increase in apoptotic cells (Suppl. Fig 1B). We also 
reasoned that inhibiting system xc– transport activity should result in decreased amounts of 
intracellular antioxidants (e.g., cysteine and GSH), and a subsequent increase in pro-oxidants. 
Intracellular ROS levels were measured by DCF staining to determine if there was a more pro-
oxidant state that could contribute to the increased cell death observed after SSZ treatment. 
Indeed, treatment of the glioma cells with 500 μM SSZ resulted in significantly greater amounts 
of intracellular ROS compared to non-treated cells (Fig. 1E).  
 
Synergistic Cytotoxicity in Glioma between the Chemotherapeutic Agent Temozolomide and an 
Inhibitor of System Xc– 
We evaluated whether inhibition of system xc– could change the chemosensitivity or 
chemoresistance of U251 cells to TMZ, the standard chemotherapeutic agent used to treat newly 
diagnosed GBM patients. We first examined whether pharmacologically inhibiting system xc– 
with SSZ would increase the toxicity of TMZ. Parental U251 cells were treated for 3 days with 
increasing doses of SSZ (50, 100, 200, 400, 800, or 1600 μM) and increasing doses of TMZ 
(12.5, 25, 50, 100, 200, 400, or 800 μM). A combination index (CI)-isobologram equation was 
used to quantitatively determine drug interactions, where CI<1 indicates synergism, 1 indicates 
an additive effect, and >1 indicates antagonism (23). A synergistic effect was seen with all doses 
of TMZ and 50 μM of SSZ as well as other lower doses of both drugs (Fig. 1F), indicating that 
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inhibition of system xc– may sensitize glioma cells to chemotherapy. SSZ doses at 800 μM or 
higher showed additive or antagonistic effects.  
 
SLC7A11 Over-expression Confers Resistance to Oxidative Stress 
To gain insight in the function of SLC7A11 in human glioma, we established stable U251 over-
expressing and knock-down lines using lentiviral vector-mediated gene transfer and RNA 
silencing technology. The SLC7A11 over-expressing cells expressed 10-fold more SLC7A11 
mRNA than did control cells (Fig. 2A), and this was accompanied by greater xCT protein 
expression, as shown by Western blot analysis (Suppl. Fig. 2A) and immunocytochemistry (Fig. 
2B). Five different shRNA clones to target different regions of SLC7A11 were tested to obtain 
the most efficient knock-down compared to empty vector control. Because the shSLC7A11_ 
TRCN0000043126 construct suppressed gene and total protein expression the most in the 
transduced U251 cells (Suppl. Fig. 2B), which was confirmed by immunocytochemistry (data 
not shown), we chose it for further analysis. The SLC7A11-knock-down cell expressed 
significantly less SLC7A11 mRNA than did the cells transduced with an empty vector (Fig. 2A) 
Knock-down of xCT (SLC7A11) protein expression was confirmed by immunocytochemistry 
(Fig. 2B).  
 To assess whether modification of SLC7A11 expression affects system xc– transport 
activity, we measured glutamate release into the media. SLC7A11 over-expressing cells released 
significantly more glutamate compared to control cells, while SLC7A11-knock-down cells 
released significantly less, indicating the cystine influx: glutamate efflux transporter was 
functional (Fig. 2C). We found that enhancement or suppression of SLC7A11 expression in 
established cell lines did not influence cell proliferation (Fig. 2E) or cell viability (Fig. 2F). 
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However, a soft agar assay revealed that the SLC7A11 over-expressing cells had higher 
anchorage-independent cell growth while the SLC7A11 knock-down cells had lower anchorage-
independent cell growth, indicating that the SLC7A11 over-expressing cells may be more 
tumorigenic (Fig. 2D). 
 Because system xc–, or more specifically its catalytic subunit xCT, plays an important 
role in regulating GSH levels, we evaluated intracellular GSH and ROS in the SLC7A11-
modified U251 lines. Under basal conditions, the SLC7A11 knock-down cells had significantly 
lower intracellular GSH levels as compared to their respective controls (Fig. 3A), and this 
correlated with significantly higher intracellular ROS levels (Fig. 3B). Although the SLC7A11 
over-expressing U251 cells did not have higher total intracellular GSH levels than the control, 
despite increased xCT expression, they did have significantly lower intracellular ROS levels 
under basal conditions (Fig. 3B). However, under oxidative stress conditions, mimicked by 
treatment with 100 μM H2O2, the SLC7A11 over-expressing cells had significantly increased 
intracellular GSH levels as compared to under basal conditions and to control cells treated with 
H2O2 (Fig. 3C). Consistent with increased GSH levels, H2O2-treated SLC7A11 over-expressing 
cells showed markedly less H2O2-induced intracellular ROS (Suppl. Fig. 3) and less H2O2-
induced apoptosis compared to control cells (Fig. 3D).      
 
SLC7A11 Over-expression Confers Resistance to Genotoxic Stress Induced by Temozolimide 
Various types of cancer exhibit elevated GSH levels, which makes these cancers more resistant 
to chemotherapy (6). The combinatorial drug studies indicated that inhibition of system xc– with 
SSZ could increase cell killing with TMZ under low doses. We next examined whether genetic 
manipulation of SLC7A11 could modulate chemosensitivity to TMZ. The SLC7A11 over-
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expressing cells had greater viability than did control cells treated with increasing doses of TMZ, 
while the SLC7A11 knock-down cells were less viable than control cells (Fig. 4A). Consistent 
with this, the SLC7A11 over-expressing cells had a 6-fold higher IC50 value for TMZ (419 µM) 
as compared to control cells (64 µM). The increased resistance to TMZ upon SLC7A11 over-
expression was further confirmed by higher cell proliferation rates compared to the control cells 
(Fig. 4 B). In addition, the SLC7A11 over-expressing cells exhibited much less TMZ-induced 
apoptosis when treated than did control cells, while the SLC7A11 knock-down cells showed a 
large increase in the percent of apoptotic cells (Suppl. Fig. 4A). To further test whether SLC7A11 
confers resistance to TMZ by inhibiting apoptosis, we analyzed expression of cleaved caspase-3, 
a marker of apoptotic cells, by Western blot analysis. Expression of cleaved caspase-3 was 
markedly greater in all TMZ-treated cell lines, but was lower in the SLC7A11 over-expressing 
cells as compared to the SLC7A11 knock-down cells (Fig. 4C). To determine whether increased 
GSH levels contributed to the increased chemoresistance of the SLC7A11 over-expressing cells, 
we measured intracellular GSH levels cells exposed to 300 μm TMZ. Consistent with the effect 
of oxidative stress on increasing GSH levels (Fig. 3C) in SLC7A11 over-expressing cells, the 
genotoxic stress induced by TMZ resulted in a significant increase in intracellular GSH levels 
(Fig. 4D). TMZ treatment of the SLC7A11 knock-down cells did not alter GSH levels as 
compared to untreated cells (Suppl. Fig. 4B).         
 
Differential Gene Expression in SLC7A11 Over-expressing and Knock-down Glioma Cells  
RNA-sequence analysis was performed to assess gene expression changes upon SLC7A11 over-
expression and knock-down in U251 glioma. Differential expression analysis revealed over 
4,000 differential genes between SLC7A11 over-expression and respective control cells (Fig. 5A 
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and Fig. 5B), and over 3,000 differential genes when SLC7A11 is knocked down in U251 cells 
(Fig. 5A and Suppl. Fig. 5A). Gene Ontology (GO) enrichment analysis shows the number of 
GO terms that are over-represented (or under-represented) in the SLC7A11 over-expressing 
glioma (Fig. 5C) and in the SLC7A11 knock-down glioma compared to respective controls 
(Suppl. Fig. 5B), with a complete list of enriched categories included in the Supplementary Files. 
Representative GO terms indicate that several genes involved in mitochondrial biogenesis and 
mitochondrial function are up-regulated in the SLC7A11 over-expressing glioma (Figure 5C), 
suggesting that SLC7A11 over-expressing U251 cells may have altered metabolic function.   
 
SLC7A11 Over-expressing Cells have Increased Mitochondrial Biogenesis  
Morphological examination of mitochondria was performed utilizing a transmission electron 
microscope (TEM). The electron micrographs revealed relatively well-preserved mitochondria in 
the SLC7A11 modified and control cells (Fig. 6A). Magnification of the mitochondria (right 
panel of each set) shows typical double membranes, the intermembrane space, cristae, and a 
matrix. Quantification of the mitochondria in the cell lines reveals that the SLC7A11 over-
expressing glioma has significantly higher number of mitochondria present compared to control 
cells (Fig. 6B), indicating that there is increased mitochondrial biogenesis. To further confirm 
increased mitochondria number and assess mitochondrial function, cells were stained with the 
mitochondrial membrane potential ΔΨm-sensitive fluorochrome, MitoTracker Red CMXRos. 
Fluorescent microscopic examination revealed a stronger MitoTracker Red CMXRos stain in the 
SLC7A11 over-expressing glioma (Fig. 6C). Analysis of the mean fluorescence intensity showed 
significantly higher MitoTracker Red CMXRos stain in the SLC7A11 over-expressing glioma 
compared to control cells (Fig. 6D). The increased accumulation and retention of the probe 
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indicates higher mitochondrial membrane potential (ΔΨm) in the SLC7A11 over-expressing 
glioma.  
 
SLC7A11 Over-expressing Cells have Increased Oxidative Phosphorylation 
To assess cellular bioenergetics in the SLC7A11 over-expressing U251 cells, extracellular flux 
analysis was used to determine the oxygen consumption rate (OCR) which is a measurement of 
mitochondrial respiration. Basal respiration was significantly higher in the SLC7A11 over-
expressing U251 glioma compared to control cells (Fig. 7A). Basal respiration is usually 
controlled by ATP turnover and only partly by substrate oxidation and proton leak (24). 
Therefore, we next examined ATP turnover by inhibiting ATP synthase using oligomycin. 
Treatment with oligomycin revealed that the SLC7A11 over-expressing cells had higher ATP-
linked respiration (oligomycin-sensitive fraction) compared to control cells (Fig. 7B).  The 
maximal respiratory capacity was measured in the presence of carbonyl cyanide-p-
trifluoromethoxyphenyl-hydrazon (FCC), an uncoupler that causes dissipation of the proton 
gradient by carrying protons across the inner mitochondrial membrane (17). FCCP causes rapid 
depolarization of mitochondria and acceleration of electron flux through the electron transport 
chain which resulted in significantly higher mitochondrial oxidative capacity in the SLC7A11 
over-expressing glioma compared to parental U251 cells (Fig. 7C). The spare respiratory 
capacity is the ability of substrate supply and electron transport to respond to an increase in 
energy demand, and, therefore, maintenance of some spare respiratory capacity is a major factor 
defining cell survival (24). Although not statistically significant, the SLC7A11 over-expressing 
U251 glioma had increased reserve capacity (p=0.058) compared to the control cells (Fig. 7D). 
Together these data suggest that the SLC7A11 over-expressing glioma, which display higher 
basal OCR, ATP-linked respiration, mitochondrial oxidative capacity and spare respiratory 
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capacity, have higher oxidative phosphorylation. Since mitochondria are one of the main 
producers of ROS and the primary producers of ATP, we performed analysis of ATP generation 
in the SLC7A11 over-expressing cells. Consistent with the OCR data, SLC7A11 over-expressing 
cells generate more ATP compared to control cells (Fig. 7E). Despite the increased ATP 
generation, the SLC7A11 over-expressing cells had lower mitochondrial ROS compared to the 
SLC7A11 knock-down cells or the control cells (Fig. 7F). 
 
Discussion 
It has been suggested that system xc– may be a promising cancer target since it may 
sensitize tumors to conventional chemo/radiation-based therapies by lowering GSH levels (25). 
One of the causes of post-operative radiation and chemotherapy treatment failure in GBM 
patients is an increase in GSH levels that may decrease chemotherapy-associated oxidative stress 
and play a role in glutathione-mediated cellular detoxification pathways. In this work, we have 
expanded on the role system xc– plays in TMZ resistance in human glioma and have identified a 
novel mechanism that may contribute to glioma progression, via metabolic alteration. Inhibitors 
of system xc–, such as SSZ, have been put forward as possible effective therapeutic options. SSZ 
has been shown to deplete GSH levels by inhibiting the uptake of cystine, which lowers levels of 
intracellular cysteine, the rate-limiting precursor for GSH synthesis (8).  
Supporting use of system xc– inhibitors, we show that SSZ treatment of U251 glioma 
resulted in ROS-mediated cell death. In addition, SSZ treatment in combination with TMZ 
treatment had a synergistic killing effect in U251 glioma cells. By inhibiting system xc– using 
SSZ, the efficacy of TMZ was increased at lower doses in vitro. Other pharmacological 
inhibitors of xCT, such as erastin, have been shown to sensitize glioma cells to TMZ (26). This 
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suggests that use of specific system xc– inhibitors could have promise for avoiding or greatly 
reducing TMZ-associated toxicity in GBM patients. However, other factors contributing to the 
decreased cell growth and viability cannot be ruled out since SSZ has been noted to target 
several other pathways (27). SSZ has several immunomodulatory effects, including inhibition of 
NF-κB, and inhibition of GSH S-transferase, which is responsible for conjugating GSH to 
xenobiotics for detoxification (28). These off-target effects limit the conclusions drawn from 
SSZ inhibition studies of system xc– in glioma cells. Clinical trials studying the effects of SSZ for 
the treatment of malignant glioma in adults were terminated due to adverse events and toxicity 
(29). 
We circumvented the problems associated with SSZ inhibition of system xc– by 
generating stable SLC7A11 knock-down and over-expressing U251 cell lines in order to better 
understand the role system xc– plays in glioma progression. In contrast to reports that inhibition 
of system xc– with SSZ led to decreased growth and cell cycle progression in glioma (8), we did 
not observe any changes in proliferation in the SLC7A11-modified lines. One possibility is that 
system xc– does not directly modulate cell growth and previous reports of transporter inhibition 
did not take into account the off-target effects associated with SSZ use. In addition, it is possible 
that the SLC7A11 knock-down cells are able to take up enough cystine to support proliferation, 
whereas a complete SLC7A11 knock-out would decrease glioma viability and growth. Although 
proliferation of the SLC7A11 knock-down cells was not affected, their cystine uptake was 
impaired as evidenced by the significant decrease in glutamate release and GSH generation, and 
significant increase in intracellular ROS. In terms of resistance to oxidative stress, over-
expression of SLC7A11 conferred increased resistance to apoptosis, which we attributed to a 
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significant increase in GSH generation. This suggests that the primary role of system xc– is in 
redox regulation rather than protein synthesis.           
Because elevated GSH levels in cancer cells have been associated with drug resistance, 
we hypothesized that system xc– may play a role in modulating genotoxic stress induced by 
TMZ. We found that over-expression of SLC7A11 reduced the sensitivity of glioma to TMZ and 
decreased TMZ-induced apoptosis. Disruption of system xc– function by knocking down 
SLC7A11 expression to low levels increased the sensitivity to TMZ, resulting in pronounced 
apoptosis. The increased sensitivity may be partly due to the low levels of GSH because only the 
SLC7A11 over-expressing cells exhibited increased GSH production after treatment with TMZ. 
In addition, marked activation of caspase-3 in knock-down cells confirmed that suppression of 
SLC7A11 facilitated TMZ-induced activation of the apoptotic pathway.  
It may be that the SLC7A11 knock-down cells exhibit the so-called “threshold concept for 
cancer therapy,” whereby an additional increase in ROS levels by ROS-generating agents, such 
as chemotherapy drugs, pushes the endogenous levels of ROS past a cellular tolerability 
threshold (30). TMZ has also been shown to generate ROS in human glioblastoma cell lines, 
including superoxides, cytosolic H2O2, and mitochondrial H2O2, which could be suppressed by 
pretreatment with antioxidants resveratrol, vitamin C, and iron (31). Concurrent treatment of 
glioblastoma cell lines with TMZ and valproic acid (VPA), an anticonvulsant and mood-
stabilizing drug, showed an increase in ROS and GSH depletion resulting in higher apoptosis 
compared to TMZ or VPA alone (32). These data suggest that redox regulation and TMZ-
triggered ROS bursts can contribute to the sensitivity of glioma cells to chemotherapy. Indeed, 
the SLC7A11 knock-down cells exhibited a significantly greater amount of endogenous ROS 
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under basal conditions, and TMZ treatment augmented these levels because of impaired GSH 
production.  
Recently, it has been shown that glioma chemoresistance to TMZ is linked to tighter 
mitochondrial coupling and low ROS production indicating that chemoresistance is related to a 
remodeling of the electron transport chain (17). Since mitochondrial respiration generates ROS, 
and system xc– has been shown to increase the antioxidant defense mechanisms to maintain 
redox balance, we hypothesized that SLC7A11 levels in glioma may have an impact on 
mitochondrial health and function. Over-expression of SLC7A11 in U251 glioma cells resulted in 
increased mitochondrial biogenesis and enhanced mitochondrial functions, indicated by 
increased mitochondrial membrane potential (ΔΨm). This was further confirmed by increased 
mRNA levels of several genes involved in mitochondrial biogenesis and function. While knock-
down of SLC7A11 did not impair mitochondrial respiration, over-expression of SLC7A11 
significantly increased the oxygen consumption rate (OCR) which is reflective of increased 
OXPHOS, and was accompanied by an increase in ATP generation. However, SLC7A11 over-
expressing U251 glioma generated less cytosolic and mitochondrial H2O2 compared to SLC7A11 
knock-down and control cells.  
These results suggest that high expression of SLC7A11 may play a role in mitochondrial 
biogenesis and energetics. How SLC7A11 increases OXPHOS and the molecular signaling 
pathway involved have yet to be determined. The ability of cells to respond to stress is 
influenced by the energetic capacity of mitochondria, especially under conditions of increased 
energy demand. One possibility is that the SLC7A11 over-expressing cells rely more on oxidative 
phosphorylation due to an increased ATP demand. The generation of GSH relies on two ATP-
dependent steps: synthesis of γ-glutamylcysteine and then subsequent addition of cysteine to the 
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γ-glutamylcysteine. Thus, the SLC7A11 over-expressing cells may rely on higher respiratory 
rates for GSH production. Alternatively, it may be that the increased GSH generation in the 
SLC7A11 over-expressing cells prevents the accumulation of ROS-mediated defects in the 
mitochondria, thereby promoting enhanced mitochondrial respiration. Mitochondrial DNA has a 
high mutation rate and, as mtDNA mutations increase, the energy capacity of the cell declines 
until there is insufficient energy to sustain cellular function, indicating that the bioenergetic 
threshold of the cell has been reached (33). The molecular mechanisms involved and how the 
model of chemoresistance and mitochondria metabolism can be integrated warrants further 
examination.  Whether other cancer cells that over-express SLC7A11 have increased 
mitochondrial respiration and whether OXPHOS is dependent on system xc– remains to be 
explored. However, our observations provide a potential new link between system xc–, redox 
balance, and OXPHOS to promote glioma progression and survival.  
In conclusion, we have shown that over-expression of system xc– in glioma confers a 
survival advantage suggesting worse prognosis in GBM patients. Indeed, strong xCT/SLC7A11 
expression in GBM patients correlated with an infiltrative phenotype on MRI and has been 
shown to be significantly associated with shorter progression-free and overall survival (34, 35). 
Microarray gene analysis of 60 human cancer cell lines used by the National Cancer Institute for 
drug screening (NCI-60) showed that SLC7A11 expression was negatively correlated with 
sensitivity of tumor cells to anti-cancer drugs (4). Additionally, cytotoxic drugs have been shown 
to activate SLC7A11 expression in various cancer cells (36). Our data shows that over-expression 
of SLC7A11 not only promoted resistance to oxidative stress, but also implicated system xc– in 
TMZ resistance and altered metabolism in GBM. In U251 cells, over-expression of SLC7A11 
promoted increased GSH production under oxidative stress and genotoxic stress. The GSH 
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neutralized intracellular ROS and increased the survival of the cells once stressed. Over-
expression of SLC7A11 was also correlated with an increased mitochondrial metabolism, which 
may contribute to the increased chemoresistance in these cells to TMZ. Additional studies are 
warranted to explore the molecular mechanisms involved in the SLC7A11-mediated drug 
resistance and determine whether SLC7A11 may be a therapeutic target. Therefore, further 
investigation of manipulating the activity of this transporter either alone or in combination with 
other treatment modalities may lead to improved therapies and clinical outcomes of patients with 
GBM. 
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Captions for illustrations 
Fig. 1. SLC7A11/xCT is up-regulated in glioma cell lines in which inhibition of system xc– 
modulates cell survival and proliferation. (A) Real-time quantitative RT-PCR analysis of 
SLC7A11 expression in human U87 and U251 glioma cell lines compared to primary normal 
human astrocytes (pNHA). (B) Immunoblot analysis of xCT and β-actin (loading control) 
expression in U87 and U251 glioma cells compared to pNHAs. (C) Immunohistochemical 
staining for xCT in the orthotopic tumors; positive xCT staining indicated by arrows. Scale bar, 
200 μm. (D) Proliferation of U251 cells treated with increasing doses of sulfasalazine (SSZ) for 
72 h. (E) Intracellular ROS levels in U251 cells treated with or without (control) 500 μM SSZ for 
72 h. Error bars indicate SD; *, P<0.05; **, P<0.01; ***, P<0.001. (F) Combination indices (CI) 
of U251 glioma cells treated with SSZ (50, 100, 200, 400, 800 or 1600 μM) and increasing doses 
of TMZ (12.5, 25, 50, 100, 200, 400, 800 μM) to determine drug interactions. CI<1, +1, and >1 
indicate synergism, additive effect, and antagonism, respectively.  
 
Fig. 2. Viability and proliferation are not affected in stable SLC7A11-knock-down and over-
expressing U251 glioma cells. (A) Quantification of xCT (SLC7A11) mRNA in U251 glioma 
transduced with viral vector containing SLC7A11 over-expression construct or viral vector 
containing shSLC7A11 (TRCN0000043126). (B) Confocal microscopy images of SLC7A11 
over-expression and knock-down U251 cell lines stained for xCT protein (green). Cells were 
counterstained with DAPI (blue) to visualize nuclei. Scale bars, 50 μm. (C) Amount of glutamate 
released into the media by SLC7A11 over-expressing and knock-down U251 cell lines relative to 
control. (D) Quantification of anchorage-independent cell growth in SLC7A11-modified glioma 
cells compared to controls. (E) Proliferation of SLC7A11-modified glioma cells at indicated 
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time-points as measured by BrdU incorporation. (F) Viability of SLC7A11-modified glioma cells 
measured by CCK-8 assay at indicated time-points. Data shown are means from a representative 
experiment. Error bars indicate SD; *, P<0.05; **, P<0.01; ***, P<0.001. 
 
Fig. 3. SLC7A11 over-expressing U251 glioma cells are more resistant to oxidative stress. (A) 
Relative intracellular glutathione (GSH) measured in SLC7A11-modified U251s under normal 
culture conditions. (B) Relative intracellular ROS measured in SLC7A11-modified U251s under 
normal culture conditions. (C) Relative intracellular GSH measured in SLC7A11 over-expressing 
U251 glioma after 6 h treatment with 100μM H2O2. (D) Flow cytometry analysis of Annexin 
V/propidium iodide staining of SLC7A11 over-expressing and control glioma after 6 h treatment 
with 100 μM H2O2. Data shown in (A), (B) and (C) are means from a representative experiment. 
Error bars indicate SD; *, P<0.05; **, P<0.01; ***, P<0.001. 
 
Fig. 4. SLC7A11 over-expression in U251 glioma conferred increased resistance to TMZ. (A) 
Viability of SLC7A11 over-expressing and knock-down U251 cells treated for 72 h with 
increasing doses of TMZ (IC50 values are indicated). (B) Proliferation of SLC7A11 over-
expressing and knock-down U251 cells treated for 72 h with increasing doses of TMZ compared 
to respective controls. (C) Immunoblot analysis of cleaved caspase-3 and β-actin (loading 
control) in SLC7A11-modified U251 and respective control cells after treatment with 300 μM 
TMZ. (D) Relative intracellular GSH in SLC7A11 over-expressing U251 cells after treatment 
with 300 μM TMZ for 72 h. Data shown are means from a representative experiment. Error bars 
indicate SD; *, P<0.05; **, P<0.01; ***, P<0.001.            
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Fig. 5. Gene expression changes upon SLC7A11 over-expression and knock-down in U251 cells. 
(A) Global similarity of gene expression profiles between SLC7A11 over-expression (OE), 
knock-down (KD) and matched control samples. Differential expression analysis was carried out 
on biological replicate samples for all pairs of conditions using DESeq (22); the heatmap shows 
the number of differential genes, which was used as a similarity metric between conditions. (B) 
Differentially expressed genes between SLC7A11 over-expressing and control U251 cells. (C) 
Representative Gene Ontology (GO) terms enriched in genes up-regulated upon SLC7A11 over-
expression in U251 cells. GO enrichment analysis was carried out using FuncAssociate (37). 
Complete lists of enriched categories are provided in the Supplementary Data. 
 
Fig. 6. SLC7A11 over-expressing U251 glioma has increased mitochondrial biogenesis and 
increased mitochondrial membrane potential. (A) Transmission electron micrographs of 
SLC7A11-modified glioma cells and control cells. Representative mitochondria are indicated by 
a red arrow. Scale bars: 2 um (left micrograph) and 0.5 um (right micrograph) of each set. (B) 
Quantification of mitochondria per field of view (FOV) in SLC7A11 modified lines compared to 
their respective controls. (C) Fluorescent microscopic examination of the ΔΨm-dependent uptake 
and retention of MitoTracker Red CMXRos into mitochondria in SLC7A11 over-expressing 
glioma compared to parental control. Scale bars: 100 µm. (D) Quantification of the mean 
fluorescent intensity (MFI) per field of view (FOV) of MitoTracker Red CMXRos staining in the 
SLC7A11 over-expressing glioma compared to control cells. Data shown in (B) and (D) are 
means from a representative experiment. Error bars indicate SD; *, P<0.05; **, P<0.01. 
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Fig. 7. Oxygen Consumption Rates (OCR) and respiration parameters in SLC7A11 over-
expressing U251 glioma cells compared to parental U251 cells. (A) Baseline Respiratory 
Capacity (B) ATP-linked Respiration and (C) Maximal Respiratory Capacity and (D) Reserve 
Capacity calculated for the SLC7A11 over-expressing glioma compared to parental U251 cells. 
(E) Intracellular ATP normalized to cell number in SLC7A11 over-expressing glioma cells 
compared to control cells. (F) Mitochondrial ROS measured in SLC7A11-modified glioma cells 
by the MitoTracker Red CM-H2XRos dye which stains actively respiring cell, accumulates in the 
mitochondria and is dependent on the mitochondria membrane potential. Error bars indicate SD; 
*, P<0.05; **, P<0.01; ***, P<0.001. 
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